Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

Millions of older Americans who are dealing with obesity could soon get help from Medicare to cover the high costs of weight ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Expanding coverage of weight-loss drugs like blockbusters from Eli Lilly & Co. and Novo Nordisk A/S would make 12.5 million ...

The Centers for Medicare and Medicaid Services (CMS) just shared a preliminary list of generic drugs it plans to make ...

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.